Table of Contents
ISRN Pharmacology
Volume 2011, Article ID 480291, 4 pages
http://dx.doi.org/10.5402/2011/480291
Review Article

Efficacy and Safety of COX-2 Inhibitors in the Clinical Management of Arthritis: Mini Review

1Medical Writing Group, Accenture Pharmaceutical Services, Karnataka, Bangalore 560072, India
2Allied Health Sciences, Sikkim Manipal University, Karnataka, Bangalore 560008, India
3Department of Pharmaceutics, Gautham College of Pharmacy, Karnataka, Bangalore 560032, India
4Department of Pharmaceutical Chemistry, Pushpagiri College of Pharmacy, Thiruvalla, Kerala 689101, India

Received 4 February 2011; Accepted 21 March 2011

Academic Editor: J.-A. Mico

Copyright © 2011 Sam T. Mathew et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Bertolini, A. Ottani, and M. Sandrini, “Selective COX-2 inhibitors and dual acting anti-inflammatory drugs: critical remarks,” Current Medicinal Chemistry, vol. 9, no. 10, pp. 1033–1043, 2002. View at Google Scholar · View at Scopus
  2. B. Hinz and K. Brune, “Cyclooxygenase-2—10 Years later,” Journal of Pharmacology and Experimental Therapeutics, vol. 300, no. 2, pp. 367–375, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Martel-Pelletier, D. Lajeunesse, P. Reboul, and J. P. Pelletier, “Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs,” Annals of the Rheumatic Diseases, vol. 62, no. 6, pp. 501–509, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. L. Parente, “Pros and cons of selective inhibition of cyclooxygenase-2 versus dual lipoxygenase/cyclooxygenase inhibition: is two better than One?” Journal of Rheumatology, vol. 28, no. 11, pp. 2375–2382, 2001. View at Google Scholar · View at Scopus
  5. R. D. Altman, M. C. Hochberg, R. W. Moskowitz, and T. J. Schnitzer, “Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update,” Arthritis and Rheumatism, vol. 43, no. 9, pp. 1905–1915, 2000. View at Publisher · View at Google Scholar
  6. K. M. Jordan, N. K. Arden, M. Doherty et al., “EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT),” Annals of the Rheumatic Diseases, vol. 62, no. 12, pp. 1145–1155, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. M. C. Hochberg, “New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis,” Seminars in Arthritis and Rheumatism, vol. 32, no. 3, pp. 4–14, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. G. A. Green, “Understanding NSAIDs: from aspirin to COX-2,” Clinical Cornerstone, vol. 3, no. 5, pp. 50–59, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. B. J. R. Whittle, “Gastrointestinal effects of nonsteroidal anti-inflammatory drugs,” Fundamental and Clinical Pharmacology, vol. 17, no. 3, pp. 301–313, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. J. R. Vane, “Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs,” Nature: New biology, vol. 231, no. 25, pp. 232–235, 1971. View at Google Scholar · View at Scopus
  11. K. D. Rainsford, “Profile and mechanisms of gastrointestinal and other side effects of nonsteroidal anti-inflammatory drugs (NSAIDs),” American Journal of Medicine, vol. 107, no. 6, pp. 27S–36S, 1999. View at Google Scholar · View at Scopus
  12. M. C. Allison, A. G. Howatson, C. J. Torrance, F. D. Lee, and R. I. Russell, “Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs,” New England Journal of Medicine, vol. 327, no. 11, pp. 749–754, 1992. View at Google Scholar · View at Scopus
  13. L. A. García Rodríguez, C. Cattaruzzi, M. G. Troncon, and L. Agostinis, “Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs,” Archives of Internal Medicine, vol. 158, no. 1, pp. 33–39, 1998. View at Publisher · View at Google Scholar · View at Scopus
  14. L. A. García Rodríguez and H. Jick, “Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs,” Lancet, vol. 343, no. 8900, pp. 769–772, 1994. View at Publisher · View at Google Scholar
  15. M. J. S. Langman, J. Weil, P. Wainwright et al., “Risks of bleeding peptic ulcer associate with individual non-steroidal anti-inflammatory drugs,” Lancet, vol. 343, no. 8905, pp. 1075–1078, 1994. View at Publisher · View at Google Scholar · View at Scopus
  16. M. M. Wolfe, D. R. Lichtenstein, and G. Singh, “Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs,” New England Journal of Medicine, vol. 340, no. 24, pp. 1888–1899, 1999. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. J. M. Seager and C. J. Hawkey, “ABC of the upper gastrointestinal tract: indigestion and non-steroidal anti-inflammatory drugs,” British Medical Journal, vol. 323, no. 7323, pp. 1236–1239, 2001. View at Google Scholar
  18. L. Laine, “The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors,” Seminars in Arthritis and Rheumatism, vol. 32, no. 3, pp. 25–32, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. C. Bombardier, “An evidence-based evaluation of the gastrointestinal safety of coxibs,” American Journal of Cardiology, vol. 89, no. 6, pp. 3D–9D, 2002. View at Google Scholar · View at Scopus
  20. T. Grosser, S. Fries, and G. A. FitzGerald, “Biological basis for the cardiovascular consequences of COX-2 inhibition: Therapeutic challenges and opportunities,” Journal of Clinical Investigation, vol. 116, no. 1, pp. 4–15, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. C. J. Hawkey, “COX-2 inhibitors,” Lancet, vol. 353, no. 9149, pp. 307–314, 1999. View at Publisher · View at Google Scholar · View at Scopus
  22. J. L. Masferrer, B. S. Zweifel, P. T. Manning et al., “Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 8, pp. 3228–3232, 1994. View at Google Scholar · View at Scopus
  23. R. Micklewright, S. Lane, W. Linley, C. McQuade, F. Thompson, and N. Maskrey, “Review article: NSAIDs, gastroprotection and cyclo-oxygenase-II-selective inhibitors,” Alimentary Pharmacology and Therapeutics, vol. 17, no. 3, pp. 321–332, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. British National Formulary, 2005.
  25. C. J. Hawkey, “The gastroenterologist's caseload: contribution of the rheumatologist,” Seminars in Arthritis and Rheumatism, vol. 26, no. 6, pp. 11–15, 1997. View at Google Scholar · View at Scopus
  26. L. Laine, R. Smith, K. Min, C. Chen, and R. W. Dubois, “Systematic review: the lower gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs,” Alimentary Pharmacology and Therapeutics, vol. 24, no. 5, pp. 751–767, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. J. J. Deeks, L. A. Smith, and M. D. Bradley, “Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials,” British Medical Journal, vol. 325, no. 7365, pp. 619–623, 2002. View at Google Scholar · View at Scopus
  28. W. Wober, “Comparative efficacy and safety of nimesulide and diclofenac in patients with acute shoulder, and a meta-analysis of controlled studies with nimesulide,” Rheumatology, vol. 38, no. 1, pp. 33–38, 1999. View at Publisher · View at Google Scholar · View at Scopus
  29. P. W. Lucker, C. Pawlowski, I. Friederich, F. Faiella, and E. Magni, “Double-blind, randomised, multi-centre clinical study evaluating the efficacy and tolerability of nimesulide in comparison with etodalac in patients suffering from osteoarthritis of the knee,” European Journal of Rheumatology and Inflammation, vol. 14, no. 2, pp. 29–38, 1994. View at Google Scholar
  30. T. J. Schnitzer and G. Constantine, “Etodolac (Lodine) in the treatment of osteoarthritis: recent studies,” Journal of Rheumatology, vol. 24, no. 47, pp. 23–31, 1997. View at Google Scholar · View at Scopus
  31. D. H. Neustadt, “Double blind evaluation of the long-term effects of etodolac versus ibuprofen in patients with rheumatoid arthritis,” Journal of Rheumatology. Supplement, vol. 47, pp. 17–22, 1997. View at Google Scholar
  32. F. E. Silverstein, G. Faich, J. L. Goldstein et al., “Gastrointestinal toxicity with Celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and reumatoid arthritis: the CLASS study: a randomized controlled trial,” Journal of the American Medical Association, vol. 284, no. 10, pp. 1247–1255, 2000. View at Google Scholar
  33. C. Bombardier, L. Laine, A. Reicin et al., “Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis,” New England Journal of Medicine, vol. 343, no. 21, pp. 1520–1528, 2000. View at Publisher · View at Google Scholar · View at PubMed
  34. T. J. Schnitzer, G. R. Burmester, E. Mysler et al., “Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: Randomised controlled trial,” Lancet, vol. 364, no. 9435, pp. 665–674, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  35. R. C. Harris Jr., “Cyclooxygenase-2 inhibition and renal physiology,” American Journal of Cardiology, vol. 89, no. 6, pp. 10D–17D, 2002. View at Google Scholar · View at Scopus
  36. R. Komers, S. Anderson, and M. Epstein, “Renal and cardiovascular effects of selective cyclooxygenase-2 inhibitors,” American Journal of Kidney Diseases, vol. 38, no. 6, pp. 1145–1157, 2001. View at Google Scholar · View at Scopus
  37. P. Patrignani, M. G. Sciulli, S. Manarini, G. Santini, C. Cerletti, and V. Evangelista, “COX-2 is not involved in thromboxane biosynthesis by activated human platelets,” Journal of Physiology and Pharmacology, vol. 50, no. 4, pp. 661–667, 1999. View at Google Scholar · View at Scopus
  38. F. Catella-Lawson and L. J. Crofford, “Cyclooxygenase inhibition and thrombogenicity,” American Journal of Medicine, vol. 110, no. 3 supplement 1, pp. 28S–32S, 2001. View at Google Scholar
  39. B. Combe, G. Swergold, J. McLay et al., “Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study),” Rheumatology, vol. 48, no. 4, pp. 425–432, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  40. P. M. Kearney, C. Baigent, J. Godwin, H. Halls, J. R. Emberson, and C. Patrono, “Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials,” British Medical Journal, vol. 332, no. 7553, pp. 1302–1308, 2006. View at Google Scholar · View at Scopus
  41. M. F. Walter, R. F. Jacob, C. A. Day, R. Dahlborg, Y. Weng, and R. P. Mason, “Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs,” Atherosclerosis, vol. 177, no. 2, pp. 235–243, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  42. D. H. Solomon, S. Schneeweiss, R. J. Glynn et al., “Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults,” Circulation, vol. 109, no. 17, pp. 2068–2073, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  43. S. E. Garner, D. D. Fidan, R. Frankish, and L. Maxwell, “Rofecoxib for osteoarthritis,” Cochrane Database of Systematic Reviews, no. 1, Article ID CD005115, 2005. View at Google Scholar
  44. S. Garner, D. Fidan, R. Frankish et al., “Celecoxib for rheumatoid arthritis,” Cochrane Database of Systematic Reviews, no. 4, Article ID CD003831, 2002. View at Google Scholar
  45. J. E. Edwards, H. J. McQuay, and R. A. Moore, “Efficacy and safety of valdecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials,” Pain, vol. 111, no. 3, pp. 286–296, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  46. J. Zacher, D. Feldman, R. Gerli et al., “A comparison of the therapeutic efficacy and tolerability of etoricoxib and diclofenac in patients with osteoarthritis,” Current Medical Research and Opinion, vol. 19, no. 8, pp. 725–736, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus